Note: An f following a page number denotes a figure on that page; a t following a page number indicates a table on that page.

acetaminophen hepatotoxicity, 175, 176, 184f, 260
acute liver failure
drug induced, 175, 175f, 176, 178–180, 186f, 187, 189
HAV-related, 5
HBV-related, 9
HCV-related, 13, 43
Wilson’s disease and, 134
acute viral hepatitis
conditions causing, 1, 2t
general considerations, 1
hepatotropic viruses causing, 1, 2t
serologic diagnosis, 4t. See also
Hepatitis A virus; Hepatitis B virus; Hepatitis C virus; Hepatitis D virus; Hepatitis E virus
adefovir (ADV)
for chronic HBV, 30, 31, 32, 69f
for chronic HBV-HIV co-infection, 68, 69f
for compensated cirrhosis, 33
for decompensated cirrhosis, 33–34
patients with ADV resistance, 34
Advisory Committee on Immunization Practices (ACIP), 6, 10
alanine aminotransferase (ALT) levels, 26–27, 31, 46, 47, 52–53, 161, 180
alcohol use
drug-induced liver disease and, 182
NAFLD and, 80
alcoholic hepatitis treatment, 101–103
pathophysiology based treatment, 103
prognosis, 101
prognostic scoring system, 101–103
alcoholic liver disease (ALD), 98–111
HCV and, 54
HFE and, 124, 127
histological characteristics, 99t
inherited predispositions to,
258–259
mortality, 103f
nutritional guidelines, 109f
pentoxifylline decreased mortality in AH, 105f
potential new therapies, 107–108
prognosis scores, 102t
relative risk, and alcohol intake level, 100f
risk factors, 98–101
gender, 99–100
malnutrition and diet, 101
quantity of alcohol consumed, 98–99
virus, 100–101
steroids vs. placebo, 104f
survival, 99f, 104f
therapeutic algorithm for long-term management, 111f
therapeutic algorithm for management, 107f
treatment, long-term, 108–111
antiviral therapy, 108
liver transplantation, 108–111
nutritional therapy, 108
other therapies, 108. See also
Alcoholic liver disease (ALD), treatment
alcoholic liver disease (ALD), treatment, 101–108
alcoholic hepatitis, 101–103
pathophysiology based treatment, 103
prognosis, 101
prognostic scoring system, 101–103
anti-cytokine therapy, 105–106
anti-TNF treatment, 106
entanercept, 106
pentoxifylline, 105–106
antioxidants, 106–107
S-adenosyl-L-methionine, 106–107
corticosteroids, 103–105
alcoholic steatohepatitis (ASH), 80
alcoholism, 98, 181, 184
allopurinol, 244
alpha-1 antitrypsin deficiency (AAD), 140–152
cigarette smoking and, 146, 149, 151
clinical presentation, 144–147
liver disease, 144–146
other conditions, 147
panniculitis, 144, 146, 147
pulmonary disease, 146
vasculitis, 146–147
diagnosis, 147–148
general considerations, 140
genetics of, 141–143
liver biopsy results
lung disease and, 143, 144
M-type, 141
management, 148–150
pathogenesis, 143–144
PI∗∗MM phenotype, 142
PI∗SS phenotype, 143
PI∗SZ allele, 143
PI∗ZZ allele, 141–142, 145, 146, 151
prognosis, 151
schematic of PI types, 142f
selected PI variants, 141f
alpha-fetoprotein (AFP) screening, 200, 202
American Indians, decline of HAV among, 3
aminoglycosides, 226
AmpliChip, 260
Amplified Fragment Length Polymorphism (AFLP), 261
aneurysm, of hepatic artery, 242
angiotensin converting enzyme inhibitor (ACEI), 89
angiotensin receptor blocker (ARB), 89
animal studies
acetaminophen proof-of-principle study, 260
alcoholic liver disease, 105
location-specific variations in gene expression patterns, 261–262
NASH, 83
anti-cytokine therapy, 105–106
anti-TNF treatment, 106
antibiotic prophylaxis, 226–227
antiviral therapy
for acute hepatitis B, 10–11
for acute hepatitis C, 14–16
for acute hepatitis D, 17
for alcoholic liver disease, 108
for chronic hepatitis B, 29, 30–35
for chronic hepatitis C, 48–49, 51, 53, 54. See also HIV, and viral hepatitis
ascites, 221–227
ascitic fluid analysis, 222–223
ascitic fluid analysis, recommended tests, 223f
based on total protein and SAAG, 224f
refractory ascites, 224
spontaneous bacterial peritonitis
diagnosis and treatment, 227f
prevalence, 225–227
treatment, 224
aspartate aminotransferase (AST), 46, 161
autoimmune hepatitis, 164–170
classification, 168f
clinical presentation, 165–166
diagnosis, 166–167
management, 167–170
prednisone treatment, 165f
therapy, 169f
autoimmune liver disease (AILD), 155–171
autoimmune hepatitis, 164–170
ERCP vs MRCP, 157f
extrahepatic autoimmune diseases, 161f
general considerations, 153
overlap syndromes, 170–171
diagnostic criteria, 170f
prevalence of ANA in liver disease, 166f
primary biliary cirrhosis, 159, 159f, 160f, 161f, 162f
primary sclerosing cholangitis, 155, 156f, 157f, 158f, 159, 159f
survival with UDCA therapy, 163f
azathioprine, 244
bariatric surgery, 80, 86–87
Beclere model, 101–102
betaine, 88
biliary cirrhosis, 189
primary, 158f, 159, 159t, 161t, 162t, 164
bilirubin levels, 1, 4, 5
biopsy, liver
for AAT deficiency, 147–148
for alpha-1 antitrypsin deficiency
for chronic hepatitis B diagnosis, 29
for chronic hepatitis C diagnosis, 45–46, 52–53
for cirrhosis, 216
for drug-induced liver disease, 189
for hepatocellular carcinoma, 47–48
for HIV/HBV coinfection, 66
for primary biliary cirrhosis, 161–162
for Wilson’s disease, 132, 135
bone marrow suppression, 244, 246
bone marrow transplantation, 187
breast cancer, 240, 259
Budd-Chiari syndrome, 238
burned-out NASH, 77
bystander changes, 256–257

capillary liquid chromatography (LC-LC), 264–265
causal changes, 256–257
ceftaxime, 226
central nervous system, and hepatic encephalopathy, 229–231
Child-Turcotte-Pugh (CTP) score, 101–102, 216, 236, 237t, 263
children
AAT deficiency in, 144–145
acute hepatitis A in, 5
acute hepatitis B in, 10
chronic HDV and, 35
decline of HAV in, 3
hemangioma in, 196
hepatitis C transmission to, 40
NAFLD in, 79
NASH in, 79
cholangiocarcinoma, 157, 158f, 240
cholesterol, 187
cholesterol synthesis, 259
chronic hepatitis B (CHB)
clinical presentation, 27–28, 28f
diagnosis, 28–29
general considerations, 26
hepatocellular carcinoma and, 199
immune tolerant phase, 26–27
management, 30–35
chronic hepatitis B, 31–33
cirrhosis, 33–34
cirrhosis, compensated, 33
cirrhosis, compensated, 33–34, 238
combination antiviral therapies,
34–35
HBeAg negative, 31–33
HBeAg positive, 31
inactive carrier state, 31
patients with ADV resistance, 34
patients with ETV resistance, 34
patients with LAM resistance, 34
patients with LTc resistance, 34
pathogenesis, 26–27
prevalence and incidence of, 26
transmission, 26
treatment algorithm, 30f
chronic hepatitis C (CHC), 39–55
clinical manifestations, 43
combination therapy contraindications,
50f
combination therapy predictors, 49f
diagnostic tests, 44–45
epidemic, 215
epidemiology and transmission, 39–41
extrahepatic manifestations, 44f
fibrosis progression in, 258
general considerations, 39
histologic features of, 46f
laboratory tests and clinical evaluation,
43–47
liver biopsy, 45–46
natural history of, 42f
pathogenesis of chronic infection,
41–42
progression, 42–43
recommended pretreatment investigations, 50t
screening recommendations, 41t
side effects of pegylated interferon plus ribavirin, 52f
survival rates, 216
treatment, 47–55
alcohol and injecting drug use patient, 54
assessing early treatment response,
49–51
children, 53–54
decisions, 47–48
future options, 55
normal serum ALT levels and/or minimal liver disease, 52–53
options, 48–49
patients with comorbid disease due to other causes, 53
pretreatment assessment and evaluation, 49
relapsers and nonresponders to previous treatment, 54–55
chronic hepatitis C (CHC) (cont.)
side effects of antiviral therapy and
dose reduction, 51
specific patient populations, 51–55
chronic hepatitis D (CHD), 35–36
clinical presentation, 35
diagnosis, 36
HBV co-/super-infection and, 35
management, 36
pathogenesis, 35
prevalence, 35
treatment algorithm, 30f
cigarette smoking, 146, 149, 151f
cirrhosis
alcoholic, 216
alcoholic liver disease and, 99f
compensated, 33, 53, 215
cryptogenic, 77
decompensated, 33–34, 53, 137, 215, 238
HIV/HBV coinfection and, 66
NASH and, 79
primary biliary, 157
survival of different types of cirrhosis, 99f
Wilson’s disease and, 133. See also
Cirrhosis, complications of
cirrhosis, complications of, 215–231
ascites, 221–227
ascitic fluid analysis, 222–223
ascitic fluid analysis, recommended
tests, 223f
diagnosis based on total protein and
SAAG, 224f
refractory, 224
spontaneous bacterial peritonitis,
225–227, 227f
treatment, 224
general considerations, 215
hepatic encephalopathy, 229–231
hepatoportal syndrome, 227, 228f,
229
modified Child-Turcotte criteria, 216f
portal hypertension and, 216
prognosis, 215–216
variceal hemorrhage, 217–221
bacterial infections and, 218–219
balloon tamponade for, 219
diagnostic therapy for, 219
gastric varices, 220–221
management of acute, 220f
management of indexed therapies for
treatment, 217–218
management of recurrent bleeding,
219–220
primary prophylaxis, 217–218
prevention of recurrent bleeding,
217f
primary prophylaxis of, 218f
prophylaxis of recurrent, 221f
transjugular intrahepatic
prospective and shunts, 219
treatment of acute, 218–219
cyclic, 246
colon cancer, 159
cytotoxic T cells, 5–6
cytotoxic T lymphocytes (CTLs), 27
diabetes
prevalence of diabetes and NAFLD,
78f
transplantation and, 245
didanosine, 64
differentially expressed mRNA, 264
drug induced liver disease (DILI), 174–191
acetaminophen hepatotoxicity, 179, 183, 185
clinical presentation, 184–188
cholestasis, 186–187
clinical and histological patterns, 186f
fibrosis, 187
granulomas, 187
hepatitis, 186
hepatocellular necrosis, 186
neoplasms, 188
steatosis and steatohepatitis, 187
vascular lesions, 187–188
commonly implicated agents, 176–179
common groups of agents to cause
DILI, 178f
FDA regulatory actions due to
hepatotoxicity, 177f
herbal medications associated with
liver toxicity, 178f
diagnosis, 188–189
key elements in, 188f
drug development and, 179–180
INDEX

epidemiology, 174–176
hepatotoxicity background, 174–176
historically reported frequency of idiosyncratic DILI, 175
management, 189–191
key guidelines, 190
pathogenesis, 182–184
mechanism of acetaminophen hepatotoxicity, 184f
risk factors, 181, 181t, 182
troglitazone and, 179, 180
Drug Induced Liver Injury Network (DILIN), 177
dual energy X-ray absorptiometry (DEXA), 82
early virological response (EVR), 49–51
emtricitabine, 71
endoscopic ultrasound, to detect intrahepatic cholangiocarcinoma, 207
entanercept, 106
entecavir (ETV) for chronic HBV, 30, 31, 32, 69f
for chronic HBV-HIV co-infection, 68, 70
for compensated cirrhosis, 33
for decompensated cirrhosis, 33–34
patients with ETV resistance, 34
enzyme immunoassay (EIA), 44
extensive metabolism (EM), of drugs, 259
extrahepatic autoimmune diseases, 161
Fibroscan, 82
fibrosis drug induced liver disease and, 187
hepatitis C and, 258, 262
NASH and, 79, 84–85
focal nodular hyperplasia (FNH), 196–197
clinical presentation, 197
diagnosis, 197
treatment, 197
folic acid, 89
food contamination, and hepatitis A, 3
Fourier transform ion cyclotron resonance (FTICR), 265
fulminant hepatic failure (FHF) acute HBV and, 9
acute HDV and, 18
hepatitis C and, 13
hepatitis E and, 19
lamivudine treatment, 10
transplantation and, 237–238
Wilson’s disease and, 133, 137
gender differences alcoholic liver disease and, 99–100
chronic liver disease and, 261
drug-induced liver disease and, 181–182
gene expression in nonreproductive organs, 261
hemangioma and, 195
Gene Tag, 261
遗传性 AccuTag, 261
genetic counseling, and AAT deficiency, 150
-genetic disease. See Alpha-1 antitrypsin deficiency
genetic testing, for liver disease with secondary iron overload, 124
genotype testing, for HCV infection, 45
HCV, and liver transplantations, 244, 246
HCV-RNA, 19–20
health care workers, and chronic hepatitis C, 40
hemangioma, 195–196
clinical presentation, 196
diagnosis, 196
hemophilia, 62
hepatic adenoma, 188, 197–199
clinical presentation, 198
diagnosis, 198
treatment, 199
hepatic artery stenosis, 242
hepatic artery thrombosis (HAT), 242
hepatic encephalopathy (HE), 229–231
management, 230f
stages, 230f
hepatic fibrogenesis, 43
hepatitis autoimmune, 164–170
icteric, 9, 19
hepatitis A virus (HAV) acute, 1–7
clinical presentation, 4–5
decrease in incidence, 1
diagnosis, 4
epidemiology, 3–4
estimated new infections, 1, 2f
high prevalence areas, 3
incidence, U.S., 1980–2002 3f
management, 6–7
pathogenesis, 5–6
vaccination, 6–7, 7f
hepatitis B virus (HBV) acute, 7–11
antiviral therapy, 10–11
clinical presentation, 9

281
hepatitis B virus (HBV) (cont.)
decrease in incidence, 1
diagnosis, 9
distribution, 7
epidemiology, 7–9
estimated new infections, 1, 2t
incidence, 8
management, 10–11
outcome according to age at infection, 8f
pathogenesis, 9–10
transmission, 8
vaccination, 10. See also Chronic hepatitis B; Hepatitis B, in HIV-infected patient
hepatitis B, in HIV-infected patient, 65–73
adefovir, 70–71
approved FDA medications for chronic HBV infections, 68, 69t
combination therapy vs. monotherapy, 72
diagnosis, 67–68
emtricitabine, 71
entecavir, 70
epidemiology, 65
lamivudine, 70
liver-related mortality by HIV and HBsAg status, 67f
natural history, 65–67
prevention, 73
recurrent, 248
telbivudine, 71–72
tenoflovir, 71
tenoflovir vs. adefovir, 69t
treatment approach, 72–73

hepatitis C virus (HCV)
acute, 11–16
alcoholic liver disease and, 100–101
antiviral therapy, 14–16
clinical presentation, 13
decrease in incidence, 1
diagnosis, 12–13
distribution/prevalence, 12
epidemiology, 12
estimated new infections, 1, 2t
fibrosis progression in chronic, 258
hepatocellular carcinoma and, 199
management, 14–16
occupational exposure management, 14t
pathogenesis, 13
polymorphisms, 257–258
primary biliary cirrhosis and, 162
recommended routine testing recurrent, 247–248
transmission, 12. See also Chronic hepatitis C; Hepatitis C, in HIV-infected patient
hepatitis C, in HIV-infected patient, 61–65
decompensated liver disease risk, 67f
epidemiology, 61
management recommendations, 63t
natural history, 62
treatment, 62, 64t, 65
hepatitis D virus (HDV)
acute, 16–18
clinical presentation, 17
diagnosis, 16–17
distribution, 16
epidemiology, 16
management, 18
pathogenesis, 17. See also Chronic hepatitis D
hepatitis E virus (HEV)
acute, 18–20
clinical presentation, 19
diagnosis, 19
distribution, 18
epidemiology, 18–19
management, 20
pathogenesis, 19–20
transmission, 18–19
vaccines for, 20
hepatocellular carcinoma (HCC), 199–206
chronic HBV and, 28
clinical presentation, 203
diagnosis, 200
diagnosis of small HCC, 200–202
hepatic tumors and, 188
HIV/HBV coinfection and, 66
NAFLD and, 79
primary biliary cirrhosis and, 162
proteome assessments and, 267
screening, 200
staging of, 204f
transcriptome assessments and, 262
treatment, 203–206
chemoembolization, 205
liver transplantation, 203, 239–240
local ablation, 205
other therapy, 205–206
surgical resection, 203–205
hepatocellular jaundice, 180, 184–185
hepatoma. See Hepatocellular carcinoma
hepatorenal syndrome (HRS), 227–229
diagnostic criteria, 228t
hereditary hemochromatosis (HH) and iron overload, 117–128
classification of iron overload syndromes, 118t
INDEX

clinical features of HH, 122
clinical presentation, 121–123
diagnosis, 123–125
general considerations, 117
genetics of HFE-linked
hemochromatosis, 119–120
HFE as common cause of, 118–119
HFE genotype in patients with typical, 120
iron overload syndromes, 117–119
laboratory findings, 125
management, 125–126
pathophysiologic mechanisms in
HFE-related, 120–121
crypt hypothesis, 120–121
hepcidin, 121
phlebotomy treatment, 126
physical findings, 123
screening, 120, 126–128
family and population, 126–127
iron and other liver diseases, 126–127
symptoms, 122
HIV
educational programs, 40. See also HIV, and viral hepatitis
HIV, and viral hepatitis, 61–73
general considerations, 61
hepatitis B in HIV-infected patient, 65–73
approved FDA medications, 68, 69
treatment combination therapy vs.
monotherapy, 72
diagnosis, 67–68
emtricitabine, 71
entecavir, 70
epidemiology, 65
lamivudine, 70
liver-related mortality, 67
natural history, 65–67
prevention, 73
telbivudine, 71–72
tenofovir, 71
tenofovir vs. adefovir, 69
treatment approach, 72–73
hepatitis C in HIV-infected patient, 61–65
antiretroviral therapies, 62
epidemiology, 61
management recommendations, 63
natural history, 62
peginterferon plus ribavirin, 64
relative risk of decompensated liver
disease, 67
relinal treatment, 62–65
Human Liver Proteome Project (HLPP), 265–266
Hy’s Rule, 180
hypertension, and liver transplantations, 246
hypertriglyceridemia, 77
hyperturicemia, and liver transplantations, 246
hypothyroidism, 44, 123, 134, 159, 161, 164
icteric hepatitis, 9, 19
immunization
hepatitis A, 6–7, 7t
hepatitis B, 10, 73
immunosuppressive agents, and liver
transplantations, 243–244
inflammatory bowel disease, 155
injection drug use
as acute hepatitis A risk factor, 3–4
as chronic hepatitis C risk factor, 40, 54
insulin resistance drugs, 87
interferon therapy
antiviral therapy, 108
combined with ribavirin for CHC, 48, 49t
for acute hepatitis B, 7, 11
for acute hepatitis C, 15–16
for chronic hepatitis C, 127
for chronic hepatitis D, 18
for HIV/HBV co-infected patients, 68–69
for HIV/HCV co-infected patients, 62–63, 63t, 64, 64t, 65
nonresponse to treatment, 127
PEG-IFN, 48
predictors of response to, 45, 49t, 258
relapse after, 54–55
side effects, 52t, 54, 55, 248
treatment trials, 65
interferon-α, 48, 69t
interferon-γ, 6, 10
International Autoimmune Hepatitis
Group Scoring System, 167
international travel, and acute hepatitis A, 3–4
intrahepatic cholangiocarcinoma (ICC), 206–207
clinical presentation, 206
diagnosis, 206–207
treatment, 207
iron overload
chronic HCV and, 53. See also Hereditary hemochromatosis
(HH) and iron overload
INDEX

jaundice and acute hepatitis A, 5
and acute hepatitis B, 9
and acute hepatitis C, 13
hepatocellular, 180, 184–185
primary biliary cirrhosis and, 163
Kaiser Fleischer ring, 132–133
Kasabach-Merritt Syndrome, 196
Kayser-Fleischer rings, 132–133, 135
ketoconazole, 244
lactulose, 229
lamivudine (LAM) for chronic HBV, 30, 31, 32, 69t, 70
for chronic HBV-HIV co-infection, 68, 69t, 70, 71, 72, 73
for compensated cirrhosis, 33
for decompensated cirrhosis, 33–34
for fulminant hepatitis, 10
for hepatitis D, 18
patients with LAM resistance, 34–35
large volume paracentesis (LVP), 225
laser capture microdissection (LCM), 261
life style changes, and NAFLD, 85, 86
lipid-lowering agents, 88, 246, 259
lipodystrophy, 79, 80
lung disease, and alpha-1 antitrypsin deficiency, 141t, 144
Maddrey Discriminate Function (MDF), 101–102
magnetic resonance spectroscopy, 82
Major Histocompatibility Complex (MHC), 257
malnutrition alcoholic liver disease and, 101
drug-induced liver disease and, 182
mass spectrometry (MS), 265
matrix-assisted laser desorption ionization (MALDI), 265
metabolic syndrome, 77, 79, 80, 85, 87
metallic bone disease, 157, 162
metformin, 87
metronidazole, 229–230
Milan Criteria, 203
Model for End-Stage Liver Disease (MELD) scores, 101–102, 216, 236, 237
mortality and hepatitis B, 9
and hepatitis C, 19
MRI primary sclerosing cholangitis, 159
to detect hemangioma, 196
to detect hepatocellular carcinoma, 198, 200–202
to detect intrahepatic cholangiocarcinoma, 207
to detect steatosis, 81–82
to measure hepatic triglyceride content, 82
Multicenter AIDS Cohort Study (MACS), 67f
multidimensional protein identification technology (MudPIT), 266
mycophenolate mofetil, 244
N-acetyl-p-benzoquinoneamine (NAPQI), 183
National Health and Nutrition Examination Survey (NHANES), 12
neomycin, 229
non-steroidal anti-inflammatory drugs (NSAIDs), 225
nonalcoholic fatty liver disease (NALFD), 77–90
algorithm for evaluation, 81f
antioxidants, 88–89
clinical presentation, 80–82
diabetes and, 78f
drugs targeting insulin resistance, 87
epidemiology, 77–78
follic acid and, 89
HFE mutations and, 128
histologic diagnosis, 82–83
life style changes and, 86
lipid-lowering medications, 88
natural history, 79–80
obesity and metabolic issues, 78f
other novel agents, 89–90
pathogenesis, 83, 84f
potential medical and surgical strategies, 85r
proteome assessments, 267–268
receptor blockers, 89
treatment, 85
ursodeoxycholic acid and, 89
weight loss medications, 86. See also Nonalcoholic steatohepatitis
nonalcoholic steatohepatitis (NASH)
burned-out, 77
cirrhosis and, 79
coining of, 77
HFE mutations and, 128
in children, 79
inherited predispositions to, 259
obesity and metabolic issues, 79
predictors of NASH, advanced fibrosis, mortality, 84–85
<table>
<thead>
<tr>
<th>Type II diabetes and, 79. See also Nonalcoholic fatty liver disease</th>
<th>Hepatocellular carcinoma and gene expression, 262</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novel technologies, for studying CLDs, 256–269</td>
<td>Inter-individual fluctuations, 266</td>
</tr>
<tr>
<td>Database development, 257</td>
<td>Laser capture microdissection (LCM), 261</td>
</tr>
<tr>
<td>General considerations, 256–257</td>
<td>Location-specific variations, 261–262</td>
</tr>
<tr>
<td>Polymorphisms, influence on CLD, 257–260</td>
<td>mRNA identification, 260–261, 265–266</td>
</tr>
<tr>
<td>Acetaminophen proof-of-principle animal study, 260</td>
<td>Multidimensional protein identification technology, 266</td>
</tr>
<tr>
<td>Adverse side effects, 259–260</td>
<td>SAGE techniques, 260, 264</td>
</tr>
<tr>
<td>Hepatitis C, 257–258</td>
<td>Steatosis, 263–264</td>
</tr>
<tr>
<td>Hepatitis C, fibrosis progression in chronic, 258</td>
<td>Nuclear side analogues, 18</td>
</tr>
<tr>
<td>Hepatotoxicity of common drugs, 259–260</td>
<td>Combination therapies and, 34–35</td>
</tr>
<tr>
<td>Lipid lowering agents, 259</td>
<td>For chronic HBV, 30, 31, 32–33</td>
</tr>
<tr>
<td>Pharmaco-metabonomic approach, 260</td>
<td>For chronic HBV-HIV co-infection, 68</td>
</tr>
<tr>
<td>Predispositions to non-infectious liver disease, 258–259</td>
<td>For chronic HCV, 48</td>
</tr>
<tr>
<td>Treatment response or outcome prediction, 258</td>
<td>For compensated cirrhosis, 33</td>
</tr>
<tr>
<td>Viral hepatitis, 257</td>
<td>For decompensated cirrhosis, 33–34</td>
</tr>
<tr>
<td>Proteome profiling, 264–268</td>
<td>Nutritional therapy, for alcoholic liver disease, 108</td>
</tr>
<tr>
<td>Capillary liquid chromatography (LC-LC), 264–265</td>
<td>Obesity and metabolic issues</td>
</tr>
<tr>
<td>Cellular function assessment, 256–257</td>
<td>Drug-induced liver disease and, 182</td>
</tr>
<tr>
<td>Differentially expressed mRNA, 264</td>
<td>In alcoholic liver disease, 101</td>
</tr>
<tr>
<td>Human Liver Proteome Project (HLPP), 265–266</td>
<td>In liver transplantsations, 245–246</td>
</tr>
<tr>
<td>Mass spectrometry (MS), 265</td>
<td>In NALFD, 77, 78f, 80, 83, 86</td>
</tr>
<tr>
<td>Reverse phase protein arrays (RPPA), 265, 268</td>
<td>In NASH, 79</td>
</tr>
<tr>
<td>Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), 264, 267, 268</td>
<td>Octreotide, 219</td>
</tr>
<tr>
<td>Single Nucleotide Polymorphisms, 256</td>
<td>Omental fat</td>
</tr>
<tr>
<td>Transcriptome profiling, 260–264</td>
<td>Orlistat</td>
</tr>
<tr>
<td>Amplified Fragment Length Polymorphism, 261</td>
<td>Osteoporosis, 157, 162, 247</td>
</tr>
<tr>
<td>Cell culturing, 261</td>
<td>Oxidative stress, 83</td>
</tr>
<tr>
<td>Cellular function, 256–257</td>
<td>Panniculitis, 144, 146, 147</td>
</tr>
<tr>
<td>Classification schemes, 263</td>
<td>Pegylation of interferon (PEG-IFN), 48</td>
</tr>
<tr>
<td>Confounding factors, 262–263</td>
<td>Peliosis hepatitis, 187–188</td>
</tr>
<tr>
<td>Expression microarrays, 260, 264</td>
<td>Penicillamine, and Wilson’s disease, 136–138</td>
</tr>
<tr>
<td>Fibrosis and HCV infected patients, 262</td>
<td>Pentoxifylline, 88–89, 105, 105f, 106, 110</td>
</tr>
<tr>
<td>Focused studies, 266–267</td>
<td>Peritoneovenous shunts (PVS), 225</td>
</tr>
<tr>
<td>Gender differences in nonreproductive organs, 261</td>
<td>PET scanning, to detect intrahepatic cholangiocarcinoma, 207</td>
</tr>
<tr>
<td>Gene expression in healthy tissue, 261</td>
<td>Pharmacom-metabonomic approach, 260</td>
</tr>
<tr>
<td>Gene expression in NASH, 263</td>
<td>Phenytoin, 244</td>
</tr>
<tr>
<td>Gene Tag, 261</td>
<td>Polycystic ovarian syndrome, 79, 80</td>
</tr>
<tr>
<td></td>
<td>Polymorphisms, and CLD, 257–260</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen proof-of-principle animal study, 260</td>
</tr>
<tr>
<td></td>
<td>Adverse side effects, 259–260</td>
</tr>
<tr>
<td></td>
<td>Hepatitis C, 257–258</td>
</tr>
<tr>
<td></td>
<td>Hepatitis C, fibrosis progression in chronic, 258</td>
</tr>
</tbody>
</table>
polymorphisms, and CLD (cont.)
hepatotoxicity of common drugs, 259–260
lipid lowering agents, 259
pharmaco-metabonomic approach, 260
predispositions to non-infectious liver
disease, 258–259
treatment response or outcome
prediction, 258
viral hepatitis, 257
poor metabolism (PM), of drugs, 259
porphyria cutanea tarda (PCT), 128
portal hypertension, 162
post-transplant lymphoproliferative
disorder (PTLD), 247
Prader Willi syndrome, 79
pravastatin, 259
prednisolone treatment, 165
prednisone treatment, 6
pregnancy
drug-induced liver disease and, 182
hepatitis E and, 19
Wilson’s disease and, 138
primary biliary cirrhosis (PBC), 157,
159–160, 164
AMA negative vs. positive PBC, 159
clinical presentation, 160–161
complications, 162
diagnosis, 161–162
extrahepatic autoimmune diseases, 161
histologic stages, 162
management, 163–164
survival, 160
primary sclerosing cholangitis (PSC), 155–159
autoantibodies, 156
clinical presentation, 155, 156
complications, 156–157
diagnosis, 156
fat soluble deficiencies, 158
histological findings, 157
incidence of cholangiocarcinoma, 158
management, 158–159
therapies, 159
progressive airway disease, 151
proof-of-principle study, 260
proteome profiling, 264–268
capillary liquid chromatography, 264–265
cellular function assessment, 256–257
differentially expressed mRNA, 264
Human Liver Proteome Project, 265–266
mass spectrometry, 265
reverse phase protein arrays, 265, 268
two-dimensional polyacrylamide gel
electrophoresis, 264, 267, 268
pruritus, 160–161
pulmonary disease. See Lung disease, and
alpha-1 antitrypsin deficiency
quinolones, 226–227
recombinant immunoblot assay (RIBA), 44–45
refractory ascites, 224
renal dysfunction
hepatorenal syndrome, 227–229
spontaneous bacterial peritonitis and, 226
renal failure
after liver transplantation, 243
Wilson’s disease and, 133
reverse phase protein arrays (RPPA), 265, 268
proteome profiling, 265, 268
reverse transcriptase polymerase chain
reaction (RTPCR), 45
ribavirin, 48, 51, 54–55
rifaximin, 230
Roussel Uclaf Causality Asessemnt
Method (RUCAM), 189
S-adenosyl-L-methionine (SAME), 106–107
SELDI-TOF, 265, 267–268
serum-ascites albumin gradient (SAAG),
222–223
sexual activity, as acute hepatitis A risk
factor, 3
sicca syndrome, 160, 161
Single Nucleotide Polymorphisms (SNPs), 256, 258
skin cancer, 247
smoking, cigarette, 146, 149, 151
spontaneous bacterial peritonitis (SBP)
diagnosis and treatment, 227
prevalence, 225–227
transplantation and, 237
steatosis
breast cancer and, 259
chronic hepatitis C and, 46
cirrhosis and, 53, 55
hepatitis C and, 43
NAFLD and, 77, 79–80, 267–268
NASH and, 83, 85
transcriptome profiling and, 263–264
steroids
corticosteroids, 103–105
INDEX

drug-induced liver disease and, 191
hepatic adenomas and, 198
Stevens-Johnson Syndrome, 191
sunflower cataracts, 132–133
surface-enhanced laser desorption/ionization (SELDI), 265, 267
tacrolimus, 243–244, 245, 246
tamoxifen, 259
telbivudine (LdT), 71–72
for chronic HBV, 30, 31, 32–33, 69
for chronic HBV-HIV co-infection, 68
resistance to, 34
tenofovir, 69
terlipressin, 219
tests, diagnostic
AAT deficiency, 147–148
acute hepatitis A, 4
acute hepatitis B, 9
acute hepatitis C, 12–13
acute hepatitis D, 16–17
acute hepatitis E, 19
acute viral hepatitis, 4
alpha-1 antitrypsin deficiency, 147–148
autoimmune hepatitis, 166–167
chronic hepatitis B, 28–29
chronic hepatitis C, 43–47, 55
chronic hepatitis D, 36
drug induced liver disease, 188–189
drug-induced liver disease, 188–189
focal nodular hyperplasia, 197
hemangioma, 196
hepatic adenoma, 198
hepatitis A virus, 4
hepatitis B, 9
hepatitis B in HIV-infected patient, 67–68
hepatitis C, 12–13
hepatitis D, 16–17
hepatitis E, 19
hepatocellular carcinoma, 200–202
hepatorenal syndrome, 228
hepatotoxicity, 123–125
transjugular intrahepatic protosystemic shunts (TIPS), 219, 225, 236, 238
transplantation, liver, 235–248
AAT deficiency, 144, 150
acute celluare rejection, 244–245
acute hepatitis A, 5
acute hepatitis B, 9, 10
acute hepatitis C, 11
acute hepatitis D, 18
alcoholic liver disease, 108–111
Child-Turcotte-Pugh (CTP) score, 237
cholangiocarcinoma, 240
chronic hepatitis C, 39, 40, 53
cirrhosis, 225
contraindications to, 239
diabetes and, 245
disease recurrence, 247–248
for AIH, 170
fulminant hepatic failure, 237–238
general considerations, 235
gout and, 244, 246
hepatocellular carcinoma and, 203, 239–240
hypertension and renal failure, 246
hyperuricemia and gout, 246
thiazolidinediones, 87
transcriptome profiling, 260–264
Amplified Fragment Length Polymorphism, 261
cell cultivating, 261
cellular function, 256–257
classification schemes, 263
confounding factors, 262–263
expression microarrays, 260, 264
fibrosis and HCV infected patients, 262
focused studies, 266–267
gender differences in nonreproductive organs, 261
gene expression in healthy tissue, 261
gene expression in NASH, 263
Gene Tag, 261
hepatocellular carcinoma and gene expression, 262
inter-individual fluctuations in gene expression, 266
laser capture microdissection, 261
location-specific variations, 261–262
mRNA identification, 260–261, 265–266
multidimensional protein identification, 266
SAGE techniques, 260, 264
steatosis, 263–264
transfusion-associated hepatitis C, 12, 40
transient elastography (Fibroscan), 82
transjugular intrahepatic protosystemic shunts (TIPS), 219, 225, 236, 238
alcoholic liver disease, 82–83
primary biliary cirrhosis, 161–162
primary sclerosing cholangitis, 156
spontaneous bacterial peritonitis, 227
Wilson’s disease, 134–135, 135t. See also individual test
therapeutic phlebotomy, 125–126, 127
287
transplantation, liver (cont.)
immunosuppressive agents and their complications, 243–244
immunosuppressive protocols, common, 243
increase in patients awaiting, 215 indications, 235–236
infection after, 242
intrahepatic cholangiocarcinoma, 207
long-term complications, 245
long-term survival, 239, 240t, 241
medical complications, 245
obesity and metabolic issues, 245–246
operation, 241–242
osteoporosis, 247
malignancies, 247
post-operative complications, 242
primary biliary cirrhosis, 164
PSC, 158
psychosocial issues, 241
recipient, evaluation of potential, 236–241
alternative treatment, 238
need assessment, 236, 237t, 238
operative and perioperative survival, 238–239
potential for success, 238–241
renal failure after, 243
Wilson’s disease, 131, 133, 137–138
treatment studies and trials
acute hepatitis C, 15
alcoholic liver disease, 101, 104f, 108
chronic hepatitis D, 36
HCV/HIV-coinfected patients, 62, 63
hepatitis C, in HIV-infected patient, 64t
Human Liver Proteome Project, 265–266
insulin resistance, 87
interferon therapy, 15
Multicenter AIDS Cohort Study, 67f
NAFLD and NASH, 77–78, 84–85, 86–87, 88–89,
NASH in children, 79
weight loss medication, 200–202. See also Novel technologies, for studying CLDs
trientene hydrochloride, and Wilson’s disease, 137
troglitazone, 179, 180
Tumor Necrosis Factor (TNF)-α, 257–258
Tumor Necrosis Factor (TNF)-β, 257–258
tumors of liver, benign and malignant, 195–208
focal nodular hyperplasia, 196–197
clinical presentation, 197
diagnosis, 197
treatment, 197
general considerations, 195
hemangioma, 195–196
clinical presentation, 196
diagnosis, 196
hepatocellular adenoma, 197–199
clinical presentation, 198
diagnosis, 198
treatment, 199
hepatocellular carcinoma, 199–206
chemoembolization, 205
clinical presentation, 203
diagnosis, 200
diagnosis, of small HCC, 200–202
liver transplantation, 203
local ablation, 205
other therapy, 205–206
screening, 200
staging of, 204f
surgical resection, 203–205
treatment, 203–206
intrahepatic cholangiocarcinoma, 206–207
clinical presentation, 206
diagnosis, 206–207
treatment, 207
other liver tumors, 207–208
tumor markers, 207
two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), 264, 267, 268
type II diabetes
NAFLD and, 77, 80
NASH and, 79, 89
troglitazone and, 179
ultrasonography, 81–82, 159, 196, 200–202
contrast-enhanced, 82, 197, 198
endoscopic, 207
University of Toronto clinical laboratory index, 101–102
ursodeoxycholic acid (UDCA), 89, 163, 163f, 164, 170
vaccine
hepatitis E, 20. See also Immunization
variceal hemorrhage, 217–221
gastric varices, 220–221
management of acute, 220f
prevention of recurrent bleeding, 219–220
primary prophylaxis, 217–218
prophylaxis of, 218f
prophylaxis of recurrent, 221f
treatment of acute, 218–219
vasculitis, 5, 52t, 144, 146–147
vasopressin, 219
Vitamin E, as antioxidant, 87, 88, 106, 108, 138
water contamination, and hepatitis A, 3
Wilson’s disease, 131–138
clinical presentation, 132–133
diagnosis, 134
diagnosis, caveats, 135t
general considerations, 131
hepatic presentations, 133
Kayser-Fleischer rings, 132–133, 135
less common manifestations, 134t
management, 136–138
NAFLD and, 80
neurological disease and, 132, 137–138
other causes of low ceruloplasmin levels,
pathophysiology of, 131–132
pregnancy and, 138
presentations, hepatic, 133
presentations, neurological, 133
presentations, other, 134
presentations, psychiatric, 134
ruling out, 134t
screening, 136, 136t
sunflower cataracts and, 132–133
World Health Organization (WHO)
ternational standard for HBV DNA, 29
xanthelasma, 161
xanthomata, 161
zidovudine, 64
zinc, and Wilson’s disease, 137